期刊
FUTURE ONCOLOGY
卷 18, 期 29S, 页码 -出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0637
关键词
doublet toxicity; morcellation; trabectedin; uterine leiomyosarcoma; uterine myomas
类别
资金
- Bayer
- Novartis
- PharmaMar
This article is a case study of a woman with uterine leiomyosarcoma, highlighting the importance of balancing efficacy and toxicity in treatment choices for this rare disease, in order to allow patients to maintain a normal life.
Uterine fibroids are difficult to distinguish from malignant masses using standard ultrasonography; and morcellation carries the risk of disseminating occult cancer in a small but relevant group of women with an undetected uterine malignancy. In this context, we follow the progress of a woman diagnosed with uterine leiomyosarcoma after suboptimal initial surgery for an assumed fibroid. Evidence is reviewed that guided multidisciplinary tumor board decisions about optimal management approaches after local seeding and development of distant metastases, and informed treatment selection at each line of therapy. As the case study illustrates, choice of treatment for advanced soft tissue sarcomas frequently involves finding an appropriate balance between the efficacy and toxicity of available options, aiming to allow patients to maintain their normal lives. Tweetable abstract Being the ultimate travel companion of a patient with uterine leiomyosarcoma
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据